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The clinical importance of the displacement of
bilirubin from the binding to albumin in newborns
by drugs was first recognized by SILVERMAN et al.
[25] in 1954-55 for sulfisoxazol (Gantrisin®).
Since then sulfonamides are not given to icteric
newborns.
Gentamicin and other aminoglycosides are fre-
quently used for severe systemic infections of new-
born infants. Aminoglycosides bind to only a low
Proportion to plasma protein; therefore, a com-
petitive displacement of bilirubin from albumin was
considered a priory unlikely for these antibiotics.
Nevertheless, some preliminary Communications
indicated that gentamicin in icteric newborns com-
petes with bilirubin for albumin binding [6, 13,
19, 27]. Other investigators [16, 29, 30] were un-
able to demönstrate such effec^h various experi-
mental designs. ODE L L et al. [20] noted in a 1975
commentary, that they were unable to reproduce
their own results from the years 1972/73 when in
part different gentamicin preparations had been
tested. During the past years we have tested the
tolerance of various drugs in young icteric Gunn
rats [l, 15, 23, 26]. This report will summarize the
results with various gentamicin preparations and
several other aminoglycosides. For the experiments
we used the drugs äs they are marketed in ampules
rather than the pure substances. Thus, the results
include the effect of additives (solvents and pre-
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The results of our investigation caused MERCK
Company in early 1975 to remove the stabilizer
from the 10 mg ampules of Refobacin®. We have
tested primarily Refobacin® 10 mg ampules from
the production of 1973/74 and those from 1975
in comparison, later on:
l Methods
Homozygous Gunn rats, 3—5 days and one month old re-
spectively, served äs experimental animals. As genetically
determined inborn error of metabolism they lack glucuro-
nyj transferase. They cannot couple bilirubin to glucu-
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ronic acid and suffer from a life-long hyperbilirubinemia
and they usually develop a mfld to moderate kernicterus
during the first two weeks of life. Its extent can be deter-
mined histochemically in the PURKINJE' cells of the
cerebellum.
Tab. I tabulates the preparations tested and the substan-
ces contained in the stabilizers äs communicated to us by
the manufacturers. In addition to the commercial prepara-
tions we investigated the stabilizers of the 40 mg Refoba-
cin and the 10 and 40 mg Sulmycin® ampules alone äs
well äs the separate ingredients of the stabilizers benzyl
alcohol and di-Na-EDTA.
In a pilot study, we determined in heterozygous (non
icteric) young Gunn rats, the LD 50, i. e. the acute toxi-
city of the several preparations according to the method
of BEHRENS and KÄRBER. The results were calculated
from the survival rate four days after the injection.
Experimental Series l contained 3-5 day old homozy-
gous animals who received a single high dose (50-75% of
the LD 50 for heterozygous animals) of the particular test
preparation subcutaneously. Prior to the injection, and
30 minutes, 3 hours, 24 hours, and in some instances
48 hours after the injection, the serum bilirubin concen-
tration was determined in blood from the tau (direct pho-
tometric method with American Optical Bilirubinometer).
In order not to stress the neonatal rats too much by fre-
quent blood drawings the neonatal rats were tested usually
only three times. In all animals the first sample was ob-
tained before the injection, the second sample was ob-
tained in some animals after thirty minutes and others
after three hours and the third sample in most animals
after 24 hours with several at 48 hours. The graphic illus-
trations equate the pre-injection value with 100 and de-
Tab. I.
Tested preparations
Contents Additives in ampules according to manufac-
per ampule turers* Information
per ml
A. GENTAMICIN
Refobacin® X 40 mg1
Refobacin® 10 mg (Prod. 1973/74)1
Refobacin® 10 mg (Prod. 1975)1
Refobacin® 5 mg L for intrathecal application1
Sulmycin® 40 mg2
Sulmycin® 10 mg2




































Gerneb ein® 40 mg (Tobramycin)5
Sisomicin 75 mg6
Sisomidn 20 mg6
Sisomicin 4 mg for intrathecal application6
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pict the subsequent values äs percent theieof. The base
line bilirubin ranges between 7 and 10 mg% (rarely up to
11 mg%). Standard deviations for the pups of one litter
was usually less than l mg%.
As further parameters of the toxicity of the several drugs
the mortality (i. e. 4 day survival) and the weight gain
were determined.
Experimental Series 2 comprises 3 to 4 week old homo-
zygous Gunn rats. They were treated with some of the
drugs in the same dosage äs animals of series 1. Serum
bilirubin concentrations were determined at similar inter-
vals and the curves were compared with those of the new-
born rats.
Experimental Series 3 comprised 3-5 day old homozy-
gous Gunn rats who received several low dose injections
of various drugs at 24 hour intervals. Weight gain, mortal-
ity and histochemical evidence for damage to the PUR-
KINJE' cells in the cerebellum were determined. Serial
bilirubin determinations were not obtained.
The animals were küled 24 hours after the last injection
by decapitation. The brains were removed, weighed and
frozen in CO2 at - 70° C. Frozen sections of 8-10 mi-
cron thickness were stained with the following methods:
4 hematoxilin-eosin, lactate dehydrogenase (LDH),
NADH2-tetrazolium-reductase (DPN-Diaphorase,
NADH2-R) (Barka and Andersen 1965). Preparations in-
cubated without Substrate served äs controls.
With the aid of the enzyme reaction, the cytoplasm stains
äs a fine granulär blue reaction product while the nu-
cleus remains unstained. Cells with a metabolism impaired
by bilirubin do not stain [9]. The damage to PURKINJE'
cells thus demonstrated served äs an indication for the
degree of the bilirubin encephalopathy. It must be taken
noticable damage to their PURKINJE' cells between the
8th and 14th day of life even without drugs. Therefore,
we have graded the PURKINJE' cell damage by estab-
lishing two groups. The first group comprises animals
which have a loss of PURKINJE' cells (PCL) expected
for Gunn rats of a given age. The other group comprises
animals which demonstrated a further loss of cells. Heter-
ozygous and homozygous Gunn rats of the same litter
served äs a control after receiving injections of normal
saline.
2 Results
2.1 LD50 for 3—5 day old heterozygous Gunn rat
Tab. II lists the LP50 for heterozygous non-icteric
young rats äs determined by us. It confirms data
from the literäture that the tolerance for kanämy-
cin is twice äs high äs for gentamicin but that sisomi-
cin is tolerated only half äs well. Tobramycin is
somewhat better tolerated than gentamicin. It is
remarkable that the LD50 differs not only be-
tween the various aminoglycosides but also within
ampules of different pharmaceutical preparations
of the same active ingredieiit. The difference with
Sulmycin 10 and 40 mg ampules does not appear
to be too marked in Tab. II. Nevertheless, only
three of 18 animals which received 6ÖÖ, 650 and
700 mg/kg from the 10 mg ampules remained alive
äs opposed to 8 out of 13 receiving identical
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Sulmycin® 10 mg
STAB2 Sulmycin 40 mg










































1 LD5o was determined by injecting subcutaneously various doses at 50 and 100 mg Steps into 20-50 animals. The
values are rounded off.
2 _= stabilizer without the antibiotic.
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amounts from 40 mg ampules. For sisomicin the
Variation between the three tested preparations is
minimal. There are no recognizable correlations
between the added stabilizers.
Very noticable is the difference for Refobacin®
preparations. Following the injection of 600, 650
and 700 mg/kg from Refobacin® L 5 mg ampules
(lyophilized for intrathecal administration) 20 out
of 30 animals remained alive; with the same dose
from 40 mg ampules 19 of 33 survived and with
the same dose from 10 mg ampules produced in
1975 6 of 21 survived. In contrast none of 20 ani-
mals survived the lower dose of 400 or 500 mg/kg
of Refobacin® 10 mg ampules produced in 1973/
74.
Tab. II lists for each preparation the amounl of
stabilizer corresponding to the LDSO injected per
gram body weight of the rats. With stabilizers con-
taining benzyl alcohol or paraoxybenzoic acid de-
rivatives (Paraben) toxicity can be recognized from
about 0.05 ml/g. Evidently, for Refobacin® 10 mg
(made in 1973/74) not the antibiotic but the ben-
zyl alcohol content in the stabilizer determines the
LD50.
2.2 Administration of single high doses to neona-
tal homozygous Gunn rats
The maximal dose of various gentamicin prepara-
tions and tobramycin in Series l for homozygous
young rats was 400 mg/kg, ofkanamyein 1000mg/
kg. Except for Refobacin® 10mg (produjped 1973/
74) in each group at least 70% of the animals sur-
vived at least four days after the injection. This
corresponds to the survival chances of untreated
homozygous control animals of this age group.
On the other hand, only those animals receiving
tobramycin or kanamycin had a mean weight gain
of over 5 grams per day corresponding to the
weight gain of control animals. With the various
gentamicin preparations the mean weight gain
varied between 3.9 and 4.9 grams. For Sulmycin®
a trend for impaired weight gain becayse of the
stabilizer may be recognized. With RefobacinR
10 mg (produced 1973174) only one of 26 animals
survived the single dose of 200 mg/kg (correspond-
ing to 0.04 ml/g STAB Refo 10). The other ani-
mals died usually 24 to 48 hours after the injec-
tion. A single dose of 100 mg/kg (0.02 ml/g
STAB) was survived by 12 of 14 animals. Analo-
gous results were obtained after subcutaneous in-
jection of benzyl alcohol (10 mg/ml) alone or of
STAB Refo 40 without the antibiotic. Benzyl alco-
hol in a dose of 0.02 ml/g was survived by 6 of 8
animals but 0.04 ml/g was survived by none of 13
animals. Eleven of 19 animals survived 0.02 ml/g
STAB Refo 40 and one of 13 animals survived
0.04 ml/g. Weight gain was decreased after the in-
jection of benzyl alcohol solution äs well äs after
STAB Refo 40 and Refobacin® 10 mg (produced
1973/74).
Sisomicin was injected in a maximal dose of
200 mg/kg into homozygous animals based on the
LD50 of heterozygous young rats. There was no
increased mortality. There was no significant dif-
ference between the various commercial prepara-
tions. The average weight gain was 5.22 ± 1.11
grams.
Figures l to 13 demonstrate the influence of the
various aminoglycosides and the stabilizers of the
commercial preparations upon the serum bilirubin
concentrations of young homozygous Gunn rats.
Only the means are depicted. These data were not
analyzed statistically because of the variations in
regard to sampling times.
After the observations referred to above about the in-
creased occurrence of kernicterus in prematures treated
with sulfonamides, JOHNSON et al. [3, 11] reported in
1959 similar observations in young homozygous Gunn
rats. In the animal model the decrease of the serum bili-
rubin concentration occuning soon after the drug admin-
istration was clearly demonstrated. ODELL [18] corre-
lated this occurrence with the displacement of protein-
bound bilirubin from the albumtn bond by speciflc anions
including sulfonamides. Our results can be interpreted
similarly.
The first example is the lyophilized preparation
Refobacin® L 5 mg without stabilizer for intrathe-
cal use (Fig. 1). The serum bilirubin concentration
is hardly affected at all by the injection. The slight
decrease after 30 minutes corresponds to that seen
in control animals with similar injections of nor-
mal saline. Similarly, control animals usually show
somewhat higher serum bilirubin concentrations
24 hours after injection. Because of the enzyme
defect in homozygous animals the serum bilirubin
concentration rises 0.5 to 0.7 mg% per day be-
tween the third and sixth day of life. 200 and
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Fig. 1-6. Change in serum bilirubin concentration in 3-5 day old homozygous Gunn rats after one injection of antibi-
otics or stabilizer Solutions.
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Fig. 7-12. Change in serum bilirubin concentration in 3-5 day old homozygous Gunn rats after one injection of antibi-
otics or stabilizer Solutions.
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Fig. 13. Change in serum bilirubin concentration in 3-5
day old homozygous Gunn rat s after one injection of
Kanamycin.
400 mg/kg of gentamicin from Refobacin® 40mg,
ampules (Fig. 2) caused a more pronounced drop
in serum bilirubin, lasting longer than three hours.
The decrease is even more pronounced with the
higher dose.
As little äs 50 mg/kg Refobacin® from 10 mg
ampules manufactured in 1973/74 (Fig. 3) caused
a drop in serum bilirubin similar in magnitude to
that seen with 400 mg/kg from 40 mg ampules.
This allows the assumption that the responsible
factor is the associated injection of stabilizer in an
amount of 0.01 ml/g. The serum bilirubin is
lowered even more by 100 and 200 mg/kg from
10 mg ampules (1973/74 production), lasting for
over 24 hours. Very similar curves are generated if
STAB Refo 40 without antibiotic (Fig. 4) or only
benzyl alcohol (Fig. 5) "äre adminstered. Fig. 6
demonstrates graphically the lines corresponding
to 0.04 ml/g from the three preceeding illustra-
tions. The bilirubin decrease coincides so well that
the conclusion is justified that benzyl alcohol is
the solely responsible agent. After injection of
200 and 400 mg/kg gentamicin from the new Re-
fobacin® 10 mg ampules (1975 production) a si-
milar influence on the serum bilirubin concentra-
tion is not seen (Fig. 7).
Curves obtained after gentamicin injections from
Sulmycin® ampules (Fig. 8) äs well äs those after
injection of stabilizers without the antibiotic
(Fig. 10) indicate only a low bilirubin displace-
ment. A clear dose related effect from the methyl
and propyl-paraben in the stabilizers is not demon-
stratable.
Pure gentamicin (äs the diagnostic reagent of
SCHERING Corporation, Garamycin®) was tested
in addition to the 200 and 400 mg/kg doses also in
the amount of 5 mg/kg used in clinical practice.
No indications for a displacement of bilirubin
from plasma protein were found.
The curves for kanamycin (Fig. 13), tobramycin
(Fig. 9), and sisomicin (Fig. 11 and 12) do not in-
dicate bilirubin displacement. Di-Na-EDTA was
tested äs a single stabilizer substance;it döes not
influence the bilirubin concentration.
2.3 Administration of single high doses to 3—4
week old homozygous Gunn rats
In experimental series 2, three to four week old
homozygous Gunn rats received 100 to 400 mg/kg
gentamicin from Refobacin® L 5 mg ampules, 5
and 400 mg/kg from böth Sulmycin® ampules äs
well äs 5 and 100 to 400 mg/kg pure substance
(Garamycin®). As in 3 to 5 day old animals there
was no influence on the serum bilirubin concentra-
tion. Fig. 14 shows serum bilirubin curves ofthese
older rats after injection of benzyl alcohol. The
comparison with Fig. 5 (3—5 day old animals) de-
monstrates a steeper decrease in the first 30 minu-
tes and a return to the base line values within 24
hours. Several older rats tolerated in contrast to
the youiig rats 0.08 ml/g of the solution. A rather
similar picture is obtained from Fig. 15. It demon-
strates the bilirubin concentration öf the older rats
after gentamicin from Refobacin® 40 mg and Re-
fobacin® 10 mg ampules (1973/74 production).
In comparison with the young rats (Fig. 2 and 3)
the primary bilirubin decrease is steeper, the re-
turn to the original values is quicker, and higher
doses are tolerated.
The difference in the return of the bilirubin con-
centration indicates probably a different metabolic
rate for benzyl alcohol in the two age groups be-
cause of the postnatal development öf enzyme Sys-
tems [31]. In order to explain the differences in
the slope of the initial decrease, one coüld postu-
late for the younger animals either a decreased re-
sorption or it could be assumed that the effect is
not caused by the benzyl alcohol but by its meta-
bolites.
J. ierinat. Med. 4 (1976)
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Fig. 14 and 15. Serum bilirubin concentration in 3-4
week old homozygous rats after injection of benzyl al-
cohol and Refobacin® from 40 mg and 10mg ampules
(1973/74 production).
2.4 Repeated injections in low doses to young
hemozygous rats
Tab. III summarizes the survival of rats (3-5 days
old at the beginning of the experiment) after one
injection of gentamicin and after several injections
repeated at 24 hour intervals (experimental series
3) from the three tested ampules for use in infants.
The high mortality after one 200 mg/kg injection
and five 100 mg/kg injections from Refobacin®
10 mg ampules (1973/74 production) is clearly
evident. On the other hand, 21 of 24 animals sur-
vived who had received ten injections of 50 mg/kg
of this preparation. The last column lists the mean
weight gain for all animals who received ten injec-
tions if their base line weight was at least 9 grams.
Here, too, Refobacin® 10 mg (1973/74 produc-
tion) compares unfavorably with the other prepara-
tions.
Tab. IV summarizes findings in regard to the num-
ber of damaged PURKINJE' cells in the cerebellum
of the animals. Ten to eleven days after the exper-
iment when the rats were 13-16 days old the ex-
tent of the loss of PURKINJE' cells (PCL) in the
vermis of the cerebellum has been estimated
(Fig. 16—18). If animals who have had an in-
creased PCL and those who died during the exper-
imental period are added and compared to those
with the amount of PCL expected for the age, the
detrimental fact of Refobacin® 10 mg (1973Π'4
production) is quite evident. The dose of 100 mg/
kg is not different in regard to the occurrence of
kernicterus between l (not indicated in Tab. III)
2, and 5 doses; however, with 50 mg/kg a differ-
ence can be seen when 5 and 10 injections are
compared. After ten 5 mg/kg Refobacin® 10 mg
(1973/74 production) injections the adverse effect
cannot be recognized. The extent of the damage
to the ganglion cells after this low dose cannot
safely be distinguished from that in animals who
received normal saline solution or the other two
gentamicin preparations in high doses.
3 Discussion
The various methods of determining displacement
of bilirubin from albumin by drugs were compared
by YEARY and DAVIS in 1974 [32]. Among the in
vitro methods the separate sephadex-gel-filtration
of proteinbound and unbound (so-called free)
bilirubin proved particularly useful. Results ob-
tained with this method corresponded well with
the observed decrease in serum bilirubin concen-
tration of icteric Gunn rats. The authors ascribe
high potential for the testing of new drugs in-
tended for use in the perinatal period to in vivo in-
J. Perinat. Med. 4(1976)
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Enumerator: survivois/denominator: animals tested.
Tab. IV. Amount of PURKINJE' cell loss (PCL) in the cerebellum of homozygous young Gunn rats after injection of
gentamicin from various ampules for use in infants.
Preparation
Refobacin® 10 mg Prod. 1973/74
Refobacin® 10 mg Prod. 1975
Sulmycin® 10 mg
Refobacin® 10 mg Prod. 1973/74
Refobacin® 10 mg Prod. 1975
Sulmycin® 10 mg




2 X / 5 X
2X /5 X
2 X / 5 X
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5 X / 10X


















































vestigations with Gunn rats. The animal model al-
lows a better determination of the relation be-
tween time, action, and dose of a drug than in in
vitro tests and allows additional insight in the role
ofmetabolites.
The risk of kernicterus from sulfonamides was
identified first by clinicians through a careful con-
trolled study in prematures. The animal model at
that time helped to clarify the pathogenetic me-
chanism. The degradation of benzyl alcohol, ben-
zoic acid and its derivatives is similar in man and
rat. It leads to the formation of hippuric acid
which is excreted in the urine. It may be expected
that effects caused by these substances in rats may
also occur in the human.
We began our drug studies in Gunn rats in 1973
primarily to verify the protective effect of photo-
therapy for kernicterus. We wanted to test wheth-
J. Perinat. Med. 4(1976)
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Fig. 16. Heterozygous Gunn rat, cerebellum, LDH, X 100. Normal number of PURKINJE' cells.
Fig. 17. Homozygous Gunn rat, cerebellum, LDH, X 60; 10 times 50 mg/kg Sulmycin® 10mg: minimal loss of PUR-
KINJE' cells.
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Fig. 18. Homozygous Gunn rat, cerebellum, LDH, X 60; 10 times 50 mg/kg Refobacin® 10 mg (1973/74 production):
almost complete loss of PURKINJE' cells.
er the provocation of kernicterus by drugs may be
prevented by simultaneous phototherapy and this
question was soon answered in the affirmative.
During the selection of substances which displace
bilirubin from albumin and thus enhance the oc-
currence of kernicterus, we encountered gentami-
cin. When we began to use this antibiotic we were
unaware of the differences in the preparations of
the various commercial bränds. In GERMANY ad-
ditives do not have to be listed. Initially we used
(R) (R) C ^~"Refobacin^ 10 mg and Refobacin 40 mg ämpu-
les without particular preference according to the
supply. Only after we recognized the marked dif-
ference in the acute toxicity and the different in-
fluence on the serum bilirubin concentration did
we ask the manufacturer about the different addi-
tives in the ampules. From the work of BRATLID
and LANGSLET [5] it was then known that ampu-
les of diazepam of different origin do not displace
bilirubin equally from the albumin bond. STERN
and SCHIFF [27, 22] demonstrated that the biliru-
bin displacement from injectable Valium was not
caused by the diazepam, but by the benzoate in
the stabilizer. They demonstrated a similar effect
of the benzoate component in caffeine sodium
benzoate. Thus, it appeared reasonable to investi-
gate in particular the benzyl alcohol in the stabi-
lizer of Refobacin and the paraoxybenzoic acid
ester in the stabilizers of Sulmicin® and the other
tested aminoglycosides. The molecular weight of
benzyl alcohol is 108, that of methylparaben 152,
and of propylparaben 180. If it is assumed that
the portion of the molecules responsible for pro-
tein binding is situated on the phenol ring the
effect of parabene should be estimated äs at least
1/3 less than that of benzyl alcohol. In a compari-
son of the ratio of the amounts of benzyl alcohol
and benzoic acid ester (Tab. V) to that of the
active ingredient it is evident that all ampules for
use in infants contain more of them than the adult
dosage form. This fact makes a general review of
Solutions for pediatric injections highly advisable.
Furthermore, it is apparent that the amount of
critical additives in Refobacin® 10 mg ampules
(1973/74 production) is markedly higher than in
all other preparations. It is by weight twice äs high
J. Perinat. Med. 4 (1976)
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Tab. V. Comparison of the ratio: Content of benzyl alcohoi (BA) or paraben (PB) / Content of Antibiotic in various
brands.
Preparation
mg benzyl alcohoi (BA)
or mg paraben (PB)
per 10 mg antibiotic
Mass relation of the additives
in ampules
for adults for infants
Refobacin® 40 mg















as the antibiotic! Thus, it is understandable that
the addition of the stabilizer decreases the LD50
to half that of the pure substance (Tab. H). The
w) (R)LD50 of Sulmycin 40 mg and Sulmycin^
10mg ampules (Tab. II) can probably also be
related to the stabilizer addition. In order to eval-
uate the noticably lesser difference in the LD50 of
Refobacin® 40 mg, Refobacin® 10 mg (1975 pro-
duction) and Refobacin® L 5 mg as well as sisomi-
cin 75 mg and Sisomicin 20 mg the findings must
be corroborated with considerably larger numbers
of experimental animals. This is an Obligation of
the manufacturers. Because of the considerable
difference in the various ampules we think it
imparative that the package inserts do not only
list the LD50 of the drug as a pure substance, but
also that of the specific preparation.
A further question is that of the relation between
doses which damage Gunn rats and those in clinical
use. Before the recognition of the bilirubin dis-
placement, newborns received daily doses of 100
to 200 mg/kg of sulfisoxazol (Gantrisin®). A one
time injection of these doses causes a decrease in
bilirubin to about 50% of the base line value for
longer than three hours in Gunn rats. An increased
PCL can be demonstrated after only one injection
of 100 mg/kg. After 400 mg/kg the bilirubin dis-
placement persists for more than 24 hours. A de*
creased weight loss is recognizäble after l X
600 mg/kg and an increased mortality after l X
800 mg/kg (i. e. 4 to 8 times the usual daüy dose).
Only few animals survive 1000 mg/kg.
NATHENSON and co-workers [17] studied thebili-
rubinlowering effect of sodium benzoate in Gunn
rats in regard to the risk of the stabilizer in Valium®
for newborns. They were able to demonstrate a
decrease in serum bilirubin above that seen with
NaCl injections only after several intraperitoneal
injections of 35 mg/kg of sodium benzoate. This
corresponds to about 3 mg/kg of Valium®, a high
dose which is used in the treatment of neonatal
seizures. However, the authors considered only
the sodium benzoate in the Valium stabilizer
and disregarded the also present 10mg benzyl
alcohoi. Only after 200 mg/kg sodium benzoate
the bilirubin decrease resembled that seen with
200 mg/kg sulfisoxazol. In our laboratory we
tested in early experiments (l, 26) the complete
Valium stabilizer (without the active ingredient) in
3—5 day old rats. After subcutaneous injection of
an amount containing 170 mg/kg sodium benzoate
plus 50 mg/kg benzyl alcohoi (in addition to pro-
pylen glycol and ethyl alcohoi), the decrease in bili-
rubin corresponded to that after 200 mg/kg benzyl
alcohoi. NATHENSON et al. [17] concluded from
their results that injectable Valium did not consti-
tute a danger for newborns in regard to bilirubin
displacement from albumin binding, especially
considering the higher binding capacity of human
albumin, as long as recommended doses were not
grossly exceeded.
Newborns receive 3—5 mg/kg gentamicin per day
and in sepsis up to 8 mg/kg. After treating young
Gunn rats for ten days with daily doses of 5 mg/kg
Refobacin® 10 mg (1973/74 production) we found
no certain evidence of increased PCL. One injec-
tion of 50 mg/kg caused a bilirubin drop for longer
than three hours to about 80 % of the original
value. Animals receiving 50 mg/kg daily for ten
days showed an increase PCL and the weight gain
was reduced. After 100 mg/kg serum bilirubin re-
mained decreased for over 24 hours to 65 % to
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75 % of Ihc basc line value and thc mortality was
markedly incrcased (with a 10-20 times the clini·
cal dose). Only one of 26 animals survived one in-
jection of 200 mg/kg. U may be concluded that in
ncwborns with a physiological level of albumin,
and only moderate ictcrus the administration of
Rcfobacin® from thc 10 mg ampules (produced in
1973/74) alone in a moderate dose did not stress
the albumin rcscrve binding capacity disconcert-
ingly. However, with the co-occurrence of several
important factors such äs pronounced hypoalbu-
minemia, acidosis, decreased rena) function, and
Ihe administration or endogenous accumulation of
substances competing for protcin binding, one can-
not exclude competitive displacement of bilirubin
and thus a neuronal damagc by a superfluous ad-
ditive.
In comparison to Refobacin® lOmg/ampules
(1973/74 production) the demonstrable effectsof
stabilizers in all other tested commercial prepara-
tions are minimal. The question whether they are
indeed necessary for the preparation and stabiliza-
tion of aminoglycoside Solutions will not be dis-
cussed herc. The fact that in Germany, additives in
Solutions or injections do not have to be declared
cvcn if their amount is higher than that of the ac-
tive ingredient is higlily unsatisfactoiy. Every pe-
diatrician who is in a position to Order drugs for
icteric newborns and prematures would appreciate
the possibility to calculate at least the total amount
of benzoic acid derivatives which the child receives
in one day.
Wc have not found in our experiments any indica-
(ions for displacement of bilirubin by aminoglyco-
sides. Possibly, the varying data in the literature
may be explained in part by the various additives
of stabilizers. Howcver, we cannot prove this
because not all publications list the specific
commercial preparations under study.
A comparison of the change in serum bilirubin
content after Refobacin® 10mg (1973/74 pro-
duction) and benzyl alcohol in 3-5 day old and
3-4 week old homozygote Gunn rats has biologi-
cal and clinical interests in regard to the so-called
maturation of metabolic functions and should
cause a further standarization of the animal model
used. Neither in newborn humans [28] nor in
young rats [4] the degradation of benzoate to !
hippurate occurs with the same speed seen in older
individuals. Also the hippuric acid excretion by
the kidney is decreased in the neonate of both
species[10, 14,21]. j ,
DAvis and YEARY [7] studied in two day old and '
in adult homozygous Gunn rats the fate of labeiled
bilirubin after displacement from the plasma-albu-
min bond by sulfadimethoxin. The percent distri-
bution in the different tissues varied between
young and old animals. Adult animals had a
marked accumulation in the liver while in young
animals it appeared in the gastro-intestinal tract (a
probable explanation is the lack of and Z pro-
teins in the liver of the young animals). In both
adult and newborn rats the dye appeared in the
brain. Only in young rats was there a marked dif-
ference in the LD50 of sulfadimethoxin between
homozygous (icteric) and heterozygous (non-
icteric) rats - 63 mg/kg versus 770 mg/kg. The
jauthors concluded a higher sensivity for the toxic
action of free bilirubin, in the young animals.
In testing drugs on Gunn rats one has to expect
different results between adult and young animals
of varying ages. It is not clear which age group: 2,
5, or even 10 days old rats represent best the con-
ditions in newborn and premature infants (see 8).
Summary
Thc cffcct of scvcral antibiotics of aminoglycoside struc-
turc on the albumin binding of büirubin has been tested
in homozygous (jaundiccd) Gunn rats aged 3-5 days. The
following drugs were invcstigatcd: different preparations
of gcntamycin, kanamycin, tobramycin and sisomicin.
Thc animals rccoivcd 50-75 % of tjie LD50 of heterozy-
gous (non-jaundiced) Gunn rats. Mortality, wcight gain
and changcs in the plasma büirubin concentration werc
rccordcd.
It was found that the displacement of bilirubin from albu-
min is caused by the different stabilizers used and not by
the antibiotic itself. With the exception of lyophilized
preparations of gentamycin for intrathecal application all
vials contain different amounts of thesc preservatives.
Special preparations used during the newborn period con-
tain relatively more of these stabilizers.
The toxicity of the additives has already a negative in-
fluence on the LD50 for heterozygous Gunn rats when
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thc Iow dowd Rcfoboein'"' and Sulmlcin' vtali aic gtvcn.
lor Rcfobtcin ; (production 1973/74) Ihc totmncc t*
rcduced by nearly 50 / Ttic lojuäty camcd by the «Übt
U/er alone h cvtn tnorc market! \vlrn givcn tu homo-
/>£ou* (jaundirt'il) <;tmn « ll bccomcs evident tlut
bcnfyUliOttol u thc sub»tan<ro fesponable foi thc dlv
pbtcmcni of bütiubtn from Albumin. Thc urrum eon-
ccntration of billrubin üecreaso foi 3 24 hn dcpcnding
on Ihc doiic* gtvrn to Ihr ammal Itm öftere Ihr oppor·
tunily lo mraturc Ihr competitlvc displaccmcnt of bür
rtibift ca\ily and e \aelly.
t he fice, unbound, unconjugatcd bilirubin tendi (o dif-
fuse into Ihc* lipkl of fh* br^in wiih lexulltnl ketnkrlertu,
shuwn in hhtochcmkral prcpamliom of ihr
crrcbcilam of yuung huino/yguu^ (»unn uU l >m|? cn
/ymc icjctiozu (01 bclu: dcid üchyJro^cnjuu»nd N A I > H :
titKuatJum reduvldvc lh«r v) totoxii rff«x l of häuubin on
PURKIKIi : crib vuuld K drmumlialcd
l hc iftcct of Ihr Uahilimt uvcd in Ihc othcr
totcd van br nc^lcclcd undcr clinua
Ihc Uccpm^ and duration o| Ihc darcax· o!
blliiubui ailcf injcclion of Ihc dun^v*fou\ \Ubüi/
cn wai sludlcd in animal\ of diitcfcnt w U S <lays ,
J 4 vu'ckv) Difftfcnl icvulls obx-rvcd vait bc cxplaiiuxl
by Ute mure tapid metaU>liMn ot lH*n/o4ic\ in oldcr
ainrtuh, ll^wcvci', ü fcmaini an opvn i|uc\tK>n at vvhut
4i?c Cunn tat« teflccl niost pieuscly Ihc human
in ptcmaiur? and ncvvhorn
: (iunn fat.drugtibdtrubinsilbumin binding), nconalal hypvibdirubinvmu
/u&immenf<i%*Mfig
Der & von verschiedenen Aminoglykuaü Hrüpaiaten
auf dks UilUubin Albumin-Bindung.
3 5 l u^c die hornoitygote (iklcmche) (iunn Katlcn er
hielten eine hochdotierte Injektion einen AminoglykoMd*
Anlibiolicumn au« verschiedenen Handehpiaporatcn, (ir
te&tel wurden: («enlumycin, Konainycm, Tobromycin und
Sisoinicüv Die verabreichte Menge entsprach 50 bis 75 vC
der LDjo Tür gleich alte hcterozygote (nicht iktcmchc)
Gunn-Katten. l ctalitat, dowichtxanvatz und Verandenin-
gen der ScrumbUirubinkoiucnUation nach der Injektion
wurden registriert.
l s konnte klar herausgesteJU werden, daß eine üüirubin·
verdiüngu^g aus der Albuminbindung durch die aniibioli-
.vchen Mittel selbst nicht eintrat.
Abgesehen von den für intrathekate Applikation vorgese-
henen Ampullen, in denen da* Antibioticum in lyophili»
siertei Form vorliegt, enthalten die Handelspräparate un-
terschiedliche Mengen von Zusatzstoffen (Stabilisatoren).
Bemerkenswerterweise sind diese, auf den Wirkstoff be-
rechnet, in den flir Säuglinge bestimmten Ampullen, die
relativ kleine Dosen des Antibioticuim enthalten, In grö-
ßerer Menge enthalten als in den Ampullen flir Erwach-
sene,
Bereits bei heterozygoten Tieren wird die akute Toxicl·
tat - die LDSO - durch die Zusatzstoffe in den niedrig
dosieiten Refobacin®- und Sulmycin®· Ampulle n beein-
t. Beim Refobacin00 10mg (Produktion 1973/74)
wird die Verträglichkeit l a U um die Hallte redu/iert.
Noch iiiarkiiiitcr M die durch den Stabilisator de\ Kcfo·
baiur"' 10 mg (Prod 1973/74) bedingte lomitat bei
humojrygotcn l leren, l * wird nachgewiesen, dab der
darin enthaltene lleiuylalkohol bei der ikteriwhen Halle
Bilirubin aus der Albuminbindung verdrängt, Die Sei um
bUirubinkoruentrution sinkt parallel /ur DOMS für mehr
als 3 oder (Ur mehr aK 24 Stunden ab. Das Ausmatt der
kompctilivrn BiUrubinvcrdrangung kann auf diese Weise
verhältnismäßig leicht und exakt erfaßt werden. Das fiei
werdende Biltruhin verstärkt durch s^ine Neurotoxicitat
den Kcrnikteius. Das konnte eindeutig bei homo/ygoten
jungen Kalten dcmomtricrt werden, die mehrere niedriger
dovicrte li\jekliorien erhielten. Mit Hilfe histochemischer
Reaktionen flir Lactatdchydrogenase und NAUU2-Tetra-
^oliumreduktase konnte eine verstärkte Schädigung der
P U K K I N J l Zellen nachgewiesen werden.
Die Stabilisatoren aller übrigen getesteten Präparate kön-
nen als relativ unbedenklich angesehen werden.
Schließlich wurden Steilheit und Dauer dt« Hilirubinat>
falls nach Injektion der als kritisch bewerteten Stabilisa-
toren bei 3 bis 4 Wochen und 3 bis 5 Tage alten ikterl·
sehen (lUnn-Hatten verglichen. Bs zeigten sich Unter-
schiede, die auf den bekannten schneileren Metabolismus
von Ben?oateri bei den älteren Tieren zurückzuführen sein
dürften. Die l rage bleibt offen, in welchem Alter Cunn-
Ratten die Verhältnisse bei neugeborenen bzw. frühgebo-
renen Menschen am ehesten wiederspiegeln.
Schlüsselwörter; GuiuvRatte, Medikamente (Bilinibin-Albumin-Bindung). Neugeborencnhyperbilüubinamie.
Resume
influence de diverses pr^aiations d'amiooglyco&ide sur la
liaison büirubine/albumine
Des rats «Gunn» ages de 3 ä 5 jours. homozygotes
(ictoriques), ont recu une jnj^ption fortement dosoe de
Uifferentes preparations commercjabs d'un antibiotique
aminoglycoside iifin de tester la Gentamycine, la Kanamy-
Med,4 0976)
eine, la Tobramycine et la Sisomicine. U dose appliquoe
correspondait a 50 ou 75% de In LD50 pour la meine racu
de rats, äges egalement de 3 ä S jours, inuis hoterozygotcs
(non ict^riques)* On a enregistro apros injection lu letalite,
la prise de poids et les clmngcments des concentrations de
la bilirubine du sorum.
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On a pu prouver que le$ antibiotiques meines ne «deplac»
dient» pas la biliruhine liee aux aJbumineg du sarum.
En dehors des ampoules prevues pour Tappliaation in*
trathocale et dans lesquelles l'antibiotique se trouve sous
forme iyophllisee, (es autres proparations commerciales
conliennent des quantitees differentes d'additifs ou
stabilisateurs, II est interessant de relever que, bien que
renfcrmant des doses relativement faibles d'antibiotique,
le.s pmpoules prevues pour les pourrissons contiennent
davantage de ces matieres stabilisatrices que les ampoules
reservees aux adultes,
Meme chez les animaux heterozygotes, la letalite (LDso)
est infiuencee par les stabilisatours dans les ampoules a
dose minime de Refobacine®et Sulmycine® La tolerance
de la Refobacine® ä 10 mg (production 1973/74) est
presque reduite de moitie, Chez les animaux homozygotes,
la toxicite causee par le stabilisateur de la Refobacine®a
10 mg (production 1973/74) est eneore plus marquantß.
a ete etabli que chez le rat ieterique, l'alcool benzylique,
contenu dans ce stabilisateur, deplace la bilirubine fixee a
raibumine. La eoncentration de la bilirwbinö du serum
baisse paialJelement a la dose injectoe pour plus de 3 ou
pour plus de 24 heures. De cette maniere, onpcut mesurer
d'une fagon relativement simple et preise le doplaccmcnt
eompetitif de la büirubine, La bilirubine non Hee renforce
par sä neurotoxicite Kictere nucleaire, ce qui a pu ctrc
domontro clairement chez des jeunes rats homozygotes
ayant re<^u plusicurs doses plus faibles* Diverses reactions
histochimiques pour lactatdohydrogenaseet NADH2;tetra-
zoliumreductase ont permis de demontrer une deteriora-
tion importante des cellules de PURKINJE du cervclet.
Les stabilisateurs de toutes les autres preparations sont
relativement insignifiants.
Enfin on a compare la duree et la vitesse de la baisse du
taux de bilirubine apres injection de certains stabilisateurs
juges critiques chez dos rats Gunn icteriqucs ages de 3 ä 4
semaines et de 3 ä 5 jours, Les differences constatecs
somblent s'expliquer par le metabolisme accelere des
benzoates chez les animaux plus ages, On n'a toujours pas
resolu la question quol est Tage des rats Gunn qui redete
le mieux la Situation chez les enfants nouveaux-nes ou
prematures,
Mots cles: Rats Gunn, medicaments (la liaison bilirubine/albumine), hyperbilirubinemie des nouveauxnes.
Durjng the timeof editing we tested one more aminoglycosJd i, e. Amikacln (Biklin® Grünenthal/Biistol), Using the 100
mg vials (for babies) s^rumbilirubin did not decrease at all after an Injection of 500 mg/kg. When 1000 mg/kg were
given, a rather small deciease (about 10% of the starting level) could be noticed. The manufactiuers inforrned us that
neither the stabilizers of the formulation for babies not for adults contain benzoates or benzylalcohd. 5:f :
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